Suggested recent literature

Articles found by an AI-assisted PubMed search that may be missing from CancerImmunoDB, shared so that curators and users can see what is being considered.

These articles are not part of the database yet. Each one is a suggestion. The AI judged it from the title and abstract only and can be wrong. A curator reads the full paper, and only then is it added to CancerImmunoDB. A column on this page shows the curators' decision as soon as there is one.

How the list is made

  1. Search. For every year from 2021 to 2026, PubMed is searched for primary research on cancer drugs together with immune terms, and the 100 best matches of each year are taken. Every PubMed ID comes from PubMed itself, never from the AI.
  2. AI screening. Google Gemini reads each title and abstract and says whether the study tests a named anticancer drug and measures its effect on the immune system, the same scope as the database. In a first check, it marked 33 of 40 articles that curators had already accepted as likely relevant (and 1 as uncertain), and it rejected all 20 unrelated cancer articles.
  3. Curator check. Curators read each suggested paper in full and decide. Accepted papers are entered into the database with their doses, techniques and immune terms.

Why this exists: the database holds only about 10 articles a year for 2021–2024, and a plain PubMed search cannot judge whether a paper fits the scope.

574articles screened
360likely relevant
11uncertain
203not relevant
0checked by a curator
0accepted into the database
YearScreenedLikely relevant
20269961
202510081
20249872
20239245
202210052
20218549

Browse the suggestions

Reset Download the full list (CSV)

360 articles shown. “In the database” counts the entries the database already has for each drug the AI named (cell line / animal / patient).

PMIDYearArticleDrugsStudy typeCancer typeIn the databaseCurator status
38429414 2024 Modeling T cell temporal response to cancer immunotherapy rationalizes development of combinatorial treatment protocols. Nature cancer Likely relevant Tests anti-PD-1 therapy combined with anti-4-1BB agonist in vivo in mice and measures T cell dynamics and recruitment. anti-programmed cell death protein 1 (PD-1); anti-4-1BB agonist Animal unspecified cancer anti-programmed cell death protein 1 (PD-1) 0/0/0; anti-4-1BB agonist 0/0/0 Awaiting curator check
38489753 2024 The Exonuclease TREX1 Constitutes an Innate Immune Checkpoint Limiting cGAS/STING-Mediated Antitumor Immunity. Cancer immunology research Likely relevant The study investigates genetic deficiency combined with T-cell-directed immune checkpoint blockade in vivo, measuring CD8+ T cells, NK cells, and myeloid compartment remodeling. immune checkpoint blockade Animal tumor immune checkpoint blockade 0/1/0 Awaiting curator check
38518770 2024 CXCL9/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer. Cell reports. Medicine Likely relevant Evaluates intratumoral vaccination with CXCL9/10-engineered dendritic cells combined with immune checkpoint blockade in murine NSCLC models and measures T cell infiltration and activation. CXCL9/10-engineered dendritic cells; immune checkpoint blockade Animal Non-Small Cell Lung Cancer CXCL9/10-engineered dendritic cells 0/0/0; immune checkpoint blockade 0/1/0 Awaiting curator check
38520088 2024 EZH2 Inhibition Enhances PD-L1 Protein Stability Through USP22-Mediated Deubiquitination in Colorectal Cancer. Advanced science (Weinheim, Baden-Wurttemberg, Germany) Likely relevant Examines the effects of EZH2 inhibitors on PD-L1 stability and the tumor microenvironment in colorectal cancer cells. EZH2 inhibitors; anti-PD-1 Cell line colorectal cancer EZH2 inhibitors 0/0/0; anti-PD-1 14/36/0 Awaiting curator check
38550593 2024 STING agonist inflames the cervical cancer immune microenvironment and overcomes anti-PD-1 therapy resistance. Frontiers in immunology Likely relevant The study experimentally tests the STING agonist MSA-2 alone and with anti-PD-1 in murine tumor models, assessing tumor microenvironment status and immune cell infiltration. MSA-2; anti-PD-1 Animal cervical cancer MSA-2 0/0/0; anti-PD-1 14/36/0 Awaiting curator check
38581017 2024 Tumor microenvironment reprogramming combined with immunogenic enhancement by nanoemulsions potentiates immunotherapy. Journal of nanobiotechnology Likely relevant Tests melittin-encapsulated nanoemulsions combined with anti-CTLA-4 antibody in animal models, measuring cytotoxic T lymphocyte infiltration and antitumor T-cell responses. anti-CTLA-4 antibody; melittin nanoemulsions Animal colorectal tumor anti-CTLA-4 antibody 0/0/0; melittin nanoemulsions 0/0/0 Awaiting curator check
38588411 2024 Ketogenic Diet Alters the Epigenetic and Immune Landscape of Prostate Cancer to Overcome Resistance to Immune Checkpoint Blockade Therapy. Cancer research Likely relevant Evaluates combinations of immune checkpoint blockade with HDAC inhibitors and dietary interventions in cell lines and animal models, measuring extensive immune landscape changes. anti-PD1; anti-CTLA4; vorinostat Mixed prostate cancer anti-PD1 1/1/0; anti-CTLA4 0/0/0; vorinostat 53/10/3 Awaiting curator check
38643157 2024 Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation. Molecular cancer Likely relevant The study tests trametinib and PD-1/PD-L1 blockade in cancer cell lines and mouse models, measuring immune infiltrate, PD-L1 expression, and tumor microenvironment changes. trametinib; PD-1/PD-L1 axis blockade Mixed KRAS-mutant lung adenocarcinoma trametinib 59/33/6; PD-1/PD-L1 axis blockade 0/0/0 Awaiting curator check
38657120 2024 IL1R2 Blockade Alleviates Immunosuppression and Potentiates Anti-PD-1 Efficacy in Triple-Negative Breast Cancer. Cancer research Likely relevant Tests IL1R2 blockade combined with anti-PD-1 in TNBC mouse models and measures TAMs, PD-L1, and exhausted CD8+ T cells. IL1R2-neutralizing antibodies; anti-PD-1 Animal triple-negative breast cancer IL1R2-neutralizing antibodies 0/0/0; anti-PD-1 14/36/0 Awaiting curator check
38697105 2024 Next-generation anti-PD-L1/IL-15 immunocytokine elicits superior antitumor immunity in cold tumors with minimal toxicity. Cell reports. Medicine Likely relevant The study tests the immunocytokine LH05 and its combination with an oncolytic virus in animal tumor models, measuring immune cell infiltration and chemokines. LH05; anti-PD-L1/interleukin-15 (IL-15) prodrug; oncolytic virus Animal advanced and metastatic tumors (cold tumors) LH05 0/0/0; anti-PD-L1/interleukin-15 (IL-15) prodrug 0/0/0; oncolytic virus 0/0/0 Awaiting curator check
38703767 2024 Assessing personalized responses to anti-PD-1 treatment using patient-derived lung tumor-on-chip. Cell reports. Medicine Likely relevant Primary research using a patient-derived lung tumor-on-chip platform to measure ex vivo effects of immune checkpoint inhibitors (anti-PD-1) on T cell-mediated cancer cell death. anti-PD-1 Mixed non-small cell lung cancer anti-PD-1 14/36/0 Awaiting curator check
38704109 2024 Targeting tumorous Circ-E-Cadherinencoded C-E-Cad inhibits the recruitment and function of breast cancer-associated myeloid-derived suppressor cells. Pharmacological research Likely relevant The study tests anti-C-E-cad and anti-PD-1 antibodies in vivo and assesses their effect on MDSCs in breast cancer. anti-C-E-cad; anti-PD-1 Animal breast cancer anti-C-E-cad 0/0/0; anti-PD-1 14/36/0 Awaiting curator check
38711203 2024 PI3K/mTOR inhibition induces tumour microenvironment remodelling and sensitises pS6high uterine leiomyosarcoma to PD-1 blockade. Clinical and translational medicine Likely relevant The study tests PI3K/mTOR inhibitors and anti-PD-1 blockade in patient-derived xenograft (PDX) models and measures their effects on immune infiltration, macrophage repolarization, and T-cell responses. PI3K/mTOR inhibitors; anti-PD-1 Animal uterine leiomyosarcoma PI3K/mTOR inhibitors 0/0/0; anti-PD-1 14/36/0 Awaiting curator check
38713626 2024 Tumor-neutrophil cross talk orchestrates the tumor microenvironment to determine the bladder cancer progression. Proceedings of the National Academy of Sciences of the United States of America Likely relevant The study investigates targeting neutrophils or MET signaling combined with immune checkpoint blockade in mice, measuring changes in the immune microenvironment and CD8+ T cell response. immune checkpoint blockade (ICB); MET signaling inhibitors Animal bladder cancer immune checkpoint blockade (ICB) 0/0/0; MET signaling inhibitors 0/0/0 Awaiting curator check
38762492 2024 Hsc70 promotes anti-tumor immunity by targeting PD-L1 for lysosomal degradation. Nature communications Likely relevant The study tests the Hsp90 inhibitor AUY-922 in mice and measures its effect on PD-L1 expression and anti-tumor immunity. AUY-922; anti-PD-L1; anti-CTLA4 Animal unspecified AUY-922 0/0/0; anti-PD-L1 0/15/0; anti-CTLA4 0/0/0 Awaiting curator check
38789460 2024 Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer. Nature communications Likely relevant The study evaluates neoadjuvant chemo-immunotherapy (gemcitabine, cisplatin, and pembrolizumab) in bladder cancer patients and reports changes in immune gene signatures, plasma IL-9, and PD-L1/TIGIT expression. gemcitabine; cisplatin; pembrolizumab Patient muscle-invasive bladder cancer gemcitabine 30/23/10; cisplatin 18/3/11; pembrolizumab 0/0/16 Awaiting curator check
38805119 2024 Janus kinase inhibitor overcomes resistance to immune checkpoint inhibitor treatment in peritoneal dissemination of gastric cancer in C57BL/6 J mice. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association Likely relevant Evaluates the combination of immune checkpoint inhibitors and a JAK inhibitor in a mouse tumor model and measures immune cell infiltration and phenotype. anti-PD1; anti-CTLA4; Janus kinase inhibitor Animal gastric cancer anti-PD1 1/1/0; anti-CTLA4 0/0/0; Janus kinase inhibitor 0/0/0 Awaiting curator check
38819989 2024 Landscape of tumoral ecosystem for enhanced anti-PD-1 immunotherapy by gut Akkermansia muciniphila. Cell reports Likely relevant The study tests oral administration of Akkermansia muciniphila forms in combination with anti-PD-1 immunotherapy in mouse cancer models and measures various immune ecosystem changes. anti-PD-1 Animal cancer anti-PD-1 14/36/0 Awaiting curator check
38867043 2024 Obesity induces PD-1 on macrophages to suppress anti-tumour immunity. Nature Likely relevant The study investigates the effect of anti-PD-1 blockade on tumour-associated macrophages and CD8+ T cells in animal models. anti-PD-1; PD-1 blockade Animal cancer (general/unspecified tumour models) anti-PD-1 14/36/0; PD-1 blockade 0/0/0 Awaiting curator check
38900577 2024 TTK inhibitor OSU13 promotes immunotherapy responses by activating tumor STING. JCI insight Likely relevant The study investigates the TTK inhibitor OSU13 alone and combined with anti-PD-1 in cell lines, organoids, and mice, measuring STING activation and immune cell infiltration. OSU13; anti-PD-1 Mixed melanoma, colon and breast cancer OSU13 0/0/0; anti-PD-1 14/36/0 Awaiting curator check
38900864 2024 JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma. Science (New York, N.Y.) Likely relevant The study tests ruxolitinib combined with nivolumab in a clinical trial and preclinical models, measuring changes in myeloid cells, neutrophil-to-lymphocyte ratios, and T cell function. ruxolitinib; nivolumab Mixed Hodgkin lymphoma and solid tumors ruxolitinib 1/0/0; nivolumab 1/2/4 Awaiting curator check
38916448 2024 Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma. Cancer research communications Likely relevant Tests amivantamab and pembrolizumab in PDX models and measures changes in tumor-infiltrating T cells and metabolic markers associated with immunosuppression. amivantamab; pembrolizumab Animal head and neck squamous cell carcinoma and lung squamous cell carcinoma amivantamab 0/0/0; pembrolizumab 0/0/16 Awaiting curator check
38957477 2024 Faecalibaterium prausnitzii strain EXL01 boosts efficacy of immune checkpoint inhibitors. Oncoimmunology Likely relevant Tests the administration of Faecalibacterium prausnitzii strain EXL01 in tumor-bearing mice and in vitro to evaluate its effects on T cell activation and anti-tumor responses to immune checkpoint inhibitors. Faecalibacterium prausnitzii strain EXL01; immune checkpoint inhibitors Animal Non-Small Cell Lung Cancer and Advanced Melanoma Faecalibacterium prausnitzii strain EXL01 0/0/0; immune checkpoint inhibitors 0/0/0 Awaiting curator check
38973593 2024 DHODH inhibition enhances the efficacy of immune checkpoint blockade by increasing cancer cell antigen presentation. eLife Likely relevant Tests the DHODH inhibitor brequinar and immune checkpoint blockers in a mouse melanoma model, measuring antigen presentation and MHC class I. brequinar; anti-CTLA-4; anti-PD-1 Animal melanoma brequinar 0/0/0; anti-CTLA-4 1/10/7; anti-PD-1 14/36/0 Awaiting curator check
39002018 2024 Targeting CD73 limits tumor progression and enhances anti-tumor activity of anti-PD-1 therapy in intrahepatic cholangiocarcinoma. Journal of cancer research and clinical oncology Likely relevant The study tests the CD73 enzymatic inhibitor AB680 combined with PD-1 blockade or chemotherapy in murine models, measuring changes in tumor-infiltrating immune cell populations and activation markers like Granzyme B and Tbet. AB680; PD-1 antibody; gemcitabine; cisplatin Animal intrahepatic cholangiocarcinoma AB680 0/0/0; PD-1 antibody 0/3/0; gemcitabine 30/23/10; cisplatin 18/3/11 Awaiting curator check
← Previous Page 7 of 15 Next →